Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/91910
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan |
Author: | Yoshida, C. Fletcher, L. Ohashi, K. Wakita, H. Kumagai, T. Shiseki, M. Matsuei, K. Inokuchi, K. Hatta, Y. Shirasugi, Y. Yamaguchi, T. Sakamoto, J. Branford, S. Sakamaki, H. |
Citation: | International Journal of Clinical Oncology, 2012; 17(6):584-589 |
Publisher: | Springer Japan |
Issue Date: | 2012 |
ISSN: | 1341-9625 1437-7772 |
Statement of Responsibility: | Chikashi Yoshida, Linda Fletcher, Kazuteru Ohashi, Hisashi Wakita, Takashi Kumagai, Masayuki Shiseki, Kousei Matsuei, Koiti Inokuchi, Yoshihiro Hatta, Yukari Shirasugi, Toshikazu Yamaguchi, Junichi Sakamoto, Susan Branford, Hisashi Sakamaki |
Abstract: | BACKGROUND: Real-time quantitative polymerase chain reaction (RQ-PCR) has been widely used for molecular monitoring for patients with chronic myeloid leukemia (CML). Currently, RQ-PCR is not based on the concept of international scale (IS) in Japan; mainly because none of the domestic laboratories have obtained their own conversion factor (CF) which makes it possible to convert locally scaled BCR-ABL (BCR-ABL (L)) value to the IS (BCR-ABL (IS)). To join the global trend of molecular assessment of BCR-ABL in CML patients, we have tried to obtain a CF in Japan. METHODS: Samples from 55 patients were exchanged between the Japanese laboratory and the reference laboratory in Adelaide, and BCR-ABL and internal control gene transcripts of the samples were measured using RQ-PCR. The patient bias conversion method was used to determine the CF for the IS using the Bland and Altman method. RESULTS: The local CF in the Japanese laboratory was determined to be 0.87. Based on this CF, 0.1% BCR-ABL (IS), defined as major molecular response, becomes equivalent to 731 copy/μg RNA BCR-ABL (L). CONCLUSION: This study is the first to introduce a laboratory-specific CF for harmonizing RQ-PCR methodology for detecting BCR-ABL transcripts to Japan, which may open new windows for molecular assessment of CML patients in Japan. |
Keywords: | Chronic myeloid leukemia; BCR-ABL; Real-time quantitative PCR; International scale; Conversion factor |
Rights: | © Japan Society of Clinical Oncology 2011 |
DOI: | 10.1007/s10147-011-0328-x |
Published version: | http://dx.doi.org/10.1007/s10147-011-0328-x |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.